Remarks

Claims 19-43 are pending in the subject application. By this Amendment, Applicants have amended claim 30 to make the claim dependent upon the elected claims. Entry and consideration of the amendments presented herein is respectfully requested. Claims 18-43 are pending (with claims 18, 19, 22-29 and 33-43 standing withdrawn from consideration) and claims 20-21 and 30-32 are under examination and before the Examiner. Favorable consideration of the pending claims is respectfully requested.

As an initial matter, Applicants have amended the "Related Application" section of the subject specification to insert the provisional patent Application Serial No. 60/345,211 to reflect the priority claim presented in the Application Data Sheet filed December 5, 2003.

As set forth above, Applicants elect the invention of Group II, claims 20-21 and 30-32, with traverse. Applicants respectfully traverse the requirement set forth in the restriction requirement as it relates to an election of a single polynucleotide or polypeptide sequence (see page 3 of the restriction requirement dated October 4, 2004). Applicants respectfully submit that the examination of SEQ ID NOs: 7-10 and 2-6 would not place an undue search burden on the Patent Office. As is set forth in the as-filed specification at page 55, SEQ ID NOs: 7-10 are splice variants of D-amino acid oxidase (DAO) and SEQ ID NOs: 2-6 are the cDNA molecules encoding these DAO polypeptides. As indicated therein, each of SEQ ID NOs: 2-6 contain a number of common exons (e.g., exons 2, 7, 8, 9, or 10). The nucleic acid sequence encoding the various exons of the DAO polypeptides is identified in the as-filed Sequence Listing at pages 1-3 (identifying various exons in the nucleic acid sequence of SEQ ID NO: 1); thus, a sequence search including these exons would be expected to identify any prior art relevant to the DAO polypeptides and/or polynucleotides provided in the claims as they each share the above-referenced exons. Accordingly, reconsideration and withdrawal of the restriction requirement as it relates to the election of a particular amino acid or nucleic acid sequence is respectfully requested.

The Examiner is requested to call the undersigned if clarification is needed or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl